Nuvilex (PMCB)
(Delayed Data from NSDQ)
$1.89 USD
+0.04 (2.16%)
Updated Aug 14, 2024 03:58 PM ET
After-Market: $1.83 -0.06 (-3.17%) 6:34 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Nuvilex Inc. [PMCB]
Reports for Purchase
Showing records 1 - 18 ( 18 total )
Company: Nuvilex Inc.
Industry: Medical - Drugs
Company: Nuvilex Inc.
Industry: Medical - Drugs
Board Announces Business Review Committee Plans; CEO Kenneth L. Waggoner Steps Down
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Nuvilex Inc.
Industry: Medical - Drugs
Company: Nuvilex Inc.
Industry: Medical - Drugs
Company: Nuvilex Inc.
Industry: Medical - Drugs
Preliminary Unaudited Financials for Fiscal Year Ending April 30, 2022
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Nuvilex Inc.
Industry: Medical - Drugs
Additional Quality Control Assay and Confirmation of Stability of CypCaps
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Nuvilex Inc.
Industry: Medical - Drugs
CypCaps 24-Month Stability Study Successfully Completed
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Nuvilex Inc.
Industry: Medical - Drugs
Fiscal 3Q22 Results; Progress Continues Toward Clinical Hold Response
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Nuvilex Inc.
Industry: Medical - Drugs
Update Provided on Progress Toward Response to FDA Clinical Hold on IND for LAPC
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Nuvilex Inc.
Industry: Medical - Drugs
Company: Nuvilex Inc.
Industry: Medical - Drugs
Pivotal Preclinical Study Commenced in Malignant Ascites
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Nuvilex Inc.
Industry: Medical - Drugs
Headway Continues to be Made in Response to FDA Clinical Hold
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Nuvilex Inc.
Industry: Medical - Drugs
Innovative Cell-in-a-Box Technology, a Potentially Valuable Platform; Initiating Coverage With Neutral Rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Nuvilex Inc.
Industry: Medical - Drugs
SMALL-CAP SQUAWK
Provider: JGR Capital Partners
Company: Nuvilex Inc.
Industry: Medical - Drugs
We are suspending coverage of PMCB in order to focus on other areas of interest to our institutional clients.
Provider: STONEGATE CAPITAL MARKETS
Analyst: RODRIGUEZ M
Company: Nuvilex Inc.
Industry: Medical - Drugs
Company: Nuvilex Inc.
Industry: Medical - Drugs
Company: Nuvilex Inc.
Industry: Medical - Drugs
Initiation of Coverage: PMCB: Company hopes ride on novel approach to pancreatic cancer and diabetes
Provider: STONEGATE CAPITAL MARKETS
Analyst: TRANG D
|